HS
REPL icon

HighVista Strategies’s Replimune Group REPL Stock Holding History

HighVista Strategies’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,231
Closed -$304K – 149
2023
Q1 		$304K Buy
+17,231
New +$410K 0.25% 91

Other funds holding REPL

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

HighVista Strategies's REPL Position: Q2 2023 in Review

HighVista Strategies sold out of Replimune Group (REPL) in Q2 2023, closing a stake of 17,231 shares — an estimated $304K sold.

HighVista Strategies first reported a position in REPL in Q1 2023 and held it in 1 quarter. The position peaked at $304K in Q1 2023. 141 funds tracked by Wall St. Rank hold REPL as of Q2 2023.

  • HighVista Strategies reported no remaining Replimune Group position as of Q2 2023 after selling out during the quarter.
  • HighVista Strategies sold 17,231 Replimune Group shares in Q2 2023, an estimated $304K.
  • HighVista Strategies first reported a position in Replimune Group in Q1 2023 and held it in 1 quarter.
  • HighVista Strategies's Replimune Group position peaked at $304K in Q1 2023.
  • 141 funds tracked by Wall St. Rank held Replimune Group as of Q2 2023.

Based on HighVista Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.